Skip to main content

Advertisement

SpringerLink
Log in

Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

Hormone replacement therapy (HRT) has become a mainstay medical treatment option for management of gender dysphoria in transgender patients of both biologic sexes. Very little is known about the long-term effects of steroid hormone modulation on breast tissue in this population. Most of the data available on the effects of HRT on breast and reproductive tissues come from studies of postmenopausal cisgender women. Therapeutic regimens are often provider-dependent, and there, are no uniform guidelines in place for cancer surveillance in transgender patients. In this review, we present what forms of hormone therapy and hormone modulation are available to transgender patients, what is known about their effects on male and female breast tissue, and what other endogenous and exogenous factors contribute to the macroscopic and cellular changes observed.

Methods

A search for the existing literature focusing on therapeutic regimens and the effects of HRT on breast tissue provided the most current information available for this review. Recent evidence-based reports (since the year 2000) and reviews were given priority over anecdotal evidence and expert opinions when conflicting information was encountered. Older resources were considered when primary sources were needed. Given the paucity of available articles on this subject, all resources were given careful consideration.

Results

Information about the risks associated with HRT in the current literature and in this setting is limited and often conflicting, due to a scarcity of long-term studies tracking breast pathology among transgender men and women.

Conclusions

We conclude that the long-term effects of off-label pharmaceutical use for modulation of hormone levels and sexual characteristics in transgender patients have not been well studied. The tendency of steroid hormones to promote the growth of certain cancers also raises questions about the safety of differing doses and drug combinations. Further clinical and laboratory study is needed to better establish safety and dosing guidelines in transgender patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. G. Heylens, C. Verroken, S. De Cock, G. T’Sjoen, G. De Cuypere, Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder. J. Sex. Med. 11(1), 119–126 (2014)

    PubMed  Google Scholar 

  2. L. Hashemi, J. Weinreb, A.K. Weimer, R.L. Weiss, Transgender care in the primary care setting: a review of guidelines and literature. Fed. Pract. 35(7), 30–37 (2018)

    PubMed  PubMed Central  Google Scholar 

  3. E.B. Sonnenblick, A.D. Shah, Z. Goldstein, T. Reisman, Breast imaging of transgender individuals: a review. Curr. Radiol. Rep. 6(1), 1 (2018)

    PubMed  PubMed Central  Google Scholar 

  4. H.B. Nguyen, A.M. Chavez, E. Lipner, L. Hantsoo, S.L. Kornfield, R.D. Davies, C.N. Epperson, Gender-affirming hormone use in transgender individuals: impact on behavioral health and cognition. Curr. Psychiatry Rep. 20(12), 110 (2018)

    PubMed  PubMed Central  Google Scholar 

  5. W.C. Hembree, P.T. Cohen-Kettenis, L. Gooren, S.E. Hannema, W.J. Meyer, M.H. Murad, S.M. Rosenthal, J.D. Safer, V. Tangpricha, G.G. T’Sjoen, Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 102(11), 3869–3903 (2017)

    PubMed  Google Scholar 

  6. I. Gardner, J.D. Safer, Progress on the road to better medical care for transgender patients. Current Opinion in Endocrinology, Diabetes and Obesity 20(6), 553–558 (2013)

  7. J.P. Cunha, W.C. Shiel, Testosterone Replacement Therapy: Side Effects, Dosages, Treatment, Interactions, Warnings. RxList, RxList. Feb 21th, 2017. https://www.rxlist.com/consumer_testosterone-medication/drugs-condition.htm

  8. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Rockville, Md.: U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs, 2018. Internet resource

  9. J.J. Shoskes, M.K. Wilson, M.L. Spinner, Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 5(6), 834–843 (2016)

    PubMed  PubMed Central  Google Scholar 

  10. P.S. Cooke, M.K. Nanjappa, C. Ko, G.S. Prins, R.A. Hess, Estrogens in male physiology. Physiol. Rev. 97(3), 995–1043 (2017)

    PubMed  PubMed Central  Google Scholar 

  11. D.A. Gibson, P.T. Saunders, Estrogen dependent signaling in reproductive tissues—a role for estrogen receptors and estrogen related receptors. Mol. Cell. Endocrinol. 348(2), 361–372 (2012)

    CAS  PubMed  Google Scholar 

  12. T. Deli, M. Orosz, A. Jakab, Hormone replacement therapy in cancer survivors—review of the literature. Pathol. Oncol. Res. (2019)

  13. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, J. Ockene; Writing Group for the Women’s Health Initiative I, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3), 321–333 (2002)

    CAS  PubMed  Google Scholar 

  14. I. Vaz-Luis, A.H. Partridge, Exogenous reproductive hormone use in breast cancer survivors and previvors. Nat. Rev. Clin. Oncol. 15(4), 249–261 (2018)

    CAS  PubMed  Google Scholar 

  15. J. Simin, R. Tamimi, J. Lagergren, H.O. Adami, N. Brusselaers, Menopausal hormone therapy and cancer risk: an overestimated risk? Eur. J. Cancer 84, 60–68 (2017)

    CAS  PubMed  Google Scholar 

  16. Collaborative Group on Hormonal Factors in Breast Cancer T, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 350(9084), 1047–1059 (1997)

    Google Scholar 

  17. V. Tangpricha, M. den Heijer, Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 5(4), 291–300 (2017)

    CAS  PubMed  Google Scholar 

  18. M.S. Irwig, Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 5(4), 301–311 (2017)

    CAS  PubMed  Google Scholar 

  19. A. Nimrod, K.J. Ryan, Aromatization of androgens by human abdominal and breast fat tissue. J. Clin. Endocrinol. Metab. 40(3), 367–372 (1975)

    CAS  PubMed  Google Scholar 

  20. K.J. Chan, D. Jolly, J.J. Liang, J.D. Weinand, J.D. Safer, Estrogen levels do not rise with testosterone treatment for transgender men. Endocr. Pract. 24(4), 329–333 (2018)

    PubMed  Google Scholar 

  21. M. Grynberg, R. Fanchin, G. Dubost, J.C. Colau, C. Bremont-Weil, R. Frydman, J.M. Ayoubi, Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod. Biomed. Online 20(4), 553–558 (2010)

    CAS  PubMed  Google Scholar 

  22. M.H. Slagter, L.J. Gooren, A. Scorilas, C.D. Petraki, E.P. Diamandis, Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J. Histochem. Cytochem. 54(8), 905–910 (2006)

    CAS  PubMed  Google Scholar 

  23. H. Asscheman, E.J. Giltay, J.A. Megens, W.P. de Ronde, M.A. van Trotsenburg, L.J. Gooren, A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur. J. Endocrinol. 164(4), 635–642 (2011)

    CAS  PubMed  Google Scholar 

  24. R.L. Hartley, J.P. Stone, C. Temple-Oberle, Breast cancer in transgender patients: a systematic review. Part 1: male to female. Eur. J. Surg. Oncol. 44(10), 1455–1462 (2018)

    PubMed  Google Scholar 

  25. J.P. Stone, R.L. Hartley, C. Temple-Oberle, Breast cancer in transgender patients: a systematic review. Part 2: female to male. Eur. J. Surg. Oncol. 44(10), 1463–1468 (2018)

    PubMed  Google Scholar 

  26. M.N. Pollak, E.S. Schernhammer, S.E. Hankinson, Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4(7), 505–518 (2004)

    CAS  PubMed  Google Scholar 

  27. C. Carter-Su, J. Schwartz, L.S. Argetsinger, Growth hormone signaling pathways. Growth Horm. IGF Res. 28, 11–15 (2016)

    CAS  PubMed  Google Scholar 

  28. A.J. Stewart, M.D. Johnson, F.E. May, B.R. Westley, Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 265(34), 21172–21178 (1990)

    CAS  PubMed  Google Scholar 

  29. N. Nota, M. Klaver, C. Wiepjes, M. Dekker, A. Heijboer, M. Heijer Den, Increase in Insulin-like Growth Factor Levels During Cross-sex Hormone Treatment in Transgender Persons. 18th European Congress of Endocrinology (Munich, 2016)

  30. D.L. Kleinberg, T.L. Wood, P.A. Furth, A.V. Lee, Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr. Rev. 30(1), 51–74 (2009)

    CAS  PubMed  PubMed Central  Google Scholar 

  31. B.W. Hartmann, T. Laml, S. Kirchengast, A.E. Albrecht, J.C. Huber, Hormonal breast augmentation: prognostic relevance of insulin-like growth factor-I. Gynecol. Endocrinol. 12(2), 123–127 (1998)

    CAS  PubMed  Google Scholar 

  32. H.S. Narula, H.E. Carlson, Gynaecomastia—pathophysiology, diagnosis and treatment. Nat. Rev. Endocrinol. 10(11), 684–698 (2014)

    CAS  PubMed  Google Scholar 

  33. W. Ruan, M.E. Monaco, D.L. Kleinberg, Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action. Endocrinology 146(3), 1170–1178 (2005)

    CAS  PubMed  Google Scholar 

  34. D.L. Kleinberg, Role of IGF-I in normal mammary development. Breast Cancer Res. Treat. 47(3), 201–208 (1998)

    CAS  PubMed  Google Scholar 

  35. T. Nickerson, F. Chang, D. Lorimer, S.P. Smeekens, C.L. Sawyers, M. Pollak, In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61(16), 6276–6280 (2001)

    CAS  PubMed  Google Scholar 

  36. G.O. Hellawell, G.D. Turner, D.R. Davies, R. Poulsom, S.F. Brewster, V.M. Macaulay, Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62(10), 2942–2950 (2002)

    CAS  PubMed  Google Scholar 

  37. M. Gebre-Medhin, L.G. Kindblom, H. Wennbo, J. Tornell, J.M. Meis-Kindblom, Growth hormone receptor is expressed in human breast cancer. Am. J. Pathol. 158(4), 1217–1222 (2001)

    CAS  PubMed  PubMed Central  Google Scholar 

  38. J.E. Hall, Guyton and Hall textbook of medical physiology. 13th edn. (Elsevier, Philadelphia, PA)

  39. A. Pezet, H. Buteau, P.A. Kelly, M. Edery, The last proline of Box 1 is essential for association with JAK2 and functional activation of the prolactin receptor. Mol Cell Endocrinol. 129(2), 199–208 (1997)

    CAS  PubMed  Google Scholar 

  40. S. Gerlo, J.R. Davis, D.L. Mager, R. Kooijman, Prolactin in man: a tale of two promoters. Bioessays 28(10), 1051–1055 (2006)

    CAS  PubMed  PubMed Central  Google Scholar 

  41. M. Zinger, M. McFarland, N. Ben-Jonathan, Prolactin expression and secretion by human breast glandular and adipose tissue explants. J. Clin. Endocrinol. Metab. 88(2), 689–696 (2003)

    CAS  PubMed  Google Scholar 

  42. K. Foitzik, E.A. Langan, R. Paus, Prolactin and the skin: a dermatological perspective on an ancient pleiotropic peptide hormone. J. Investig. Dermatol. 129(5), 1071–1087 (2009)

    CAS  PubMed  Google Scholar 

  43. M.T. Nevalainen, E.M. Valve, P.M. Ingleton, M. Nurmi, P.M. Martikainen, P.L. Harkonen, Prolactin and prolactin receptors are expressed and functioning in human prostate. J. Clin. Investig. 99(4), 618–627 (1997)

    CAS  PubMed  Google Scholar 

  44. I.G. Camarillo, G. Thordarson, J.G. Moffat, K.M. Van Horn, N. Binart, P.A. Kelly, F. Talamantes, Prolactin receptor expression in the epithelia and stroma of the rat mammary gland. J. Endocrinol. 171(1), 85–95 (2001)

    CAS  PubMed  Google Scholar 

  45. T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. N. Am. 37(1), 67–99 (2008)

    CAS  Google Scholar 

  46. J.N. Ihle, STATs: signal transducers and activators of transcription. Cell 84(3), 331–334 (1996)

    CAS  PubMed  Google Scholar 

  47. A.R. Glass, Gynecomastia. Endocrinol. Metab. Clin. N. Am. 23(4), 825–837 (1994)

    CAS  Google Scholar 

  48. N. Cuhaci, S.B. Polat, B. Evranos, R. Ersoy, B. Cakir, Gynecomastia: clinical evaluation and management. Indian J. Endocrinol. Metab. 18(2), 150–158 (2014)

    PubMed  PubMed Central  Google Scholar 

  49. B.M. Stringer, J. Rowson, E.D. Williams, Effect of raised serum prolactin on breast development. J. Anat. 162, 249–261 (1989)

    CAS  PubMed  PubMed Central  Google Scholar 

  50. S. Mahfouda, J.K. Moore, A. Siafarikas, F.D. Zepf, A. Lin, Puberty suppression in transgender children and adolescents. Lancet Diabetes Endocrinol. 5(10), 816–826 (2017)

    PubMed  Google Scholar 

  51. G. Di Lorenzo, R. Autorino, S. Perdona, S. De Placido, Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncol. 6(12), 972–979 (2005)

    PubMed  Google Scholar 

  52. B.P.C. Kreukels, T.D. Steensma, A.L.C.D. Vries, Gender Dysphoria and Disorders of Sex Development: Progress in Care and Knowledge (Springer, Heidelberg)

  53. A. Mosenkis, R.R. Townsend, Gynecomastia and antihypertensive therapy. J. Clin. Hypertens. 6(8), 469–470 (2004)

    Google Scholar 

  54. M. Gil, B. Oliva, J. Timoner, M.A. Macia, V. Bryant, F.J. de Abajo, Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br. J. Clin. Pharmacol. 72(6), 965–968 (2011)

    CAS  PubMed  PubMed Central  Google Scholar 

  55. D. Chew, J. Anderson, K. Williams, T. May, K. Pang, Hormonal treatment in young people with gender dysphoria: a systematic review. Pediatrics. 141(4), pii: e20173742 (2018)

    Google Scholar 

  56. L.A. Tanner, L.A. Bosco, Gynecomastia associated with calcium channel blocker therapy. Arch. Intern. Med. 148(2), 379–380 (1988)

    CAS  PubMed  Google Scholar 

  57. K.B. Hammons, R.F. Edwards, W.Y. Rice, Golf-inhibiting gynecomastia associated with atorvastatin therapy. Pharmacotherapy 26(8), 1165–1168 (2006)

    PubMed  Google Scholar 

  58. Y. Nakamura, K. Yoshimoto, S. Saima, Gynaecomastia induced by angiotensin converting enzyme inhibitor. BMJ 300(6723), 541 (1990)

    CAS  PubMed  PubMed Central  Google Scholar 

  59. E.B. Lewinn, Gynecomastia during digitalis therapy; report of eight additional cases with liver-function studies. N. Engl. J. Med. 248(8), 316–320 (1953)

    CAS  PubMed  Google Scholar 

  60. L. Green, D.K. Wysowski, J.L. Fourcroy, Gynecomastia and breast cancer during finasteride therapy. N. Engl. J. Med. 335(11), 823 (1996)

    CAS  PubMed  Google Scholar 

  61. K.W. Hagberg, H.A. Divan, S.C. Fang, J.C. Nickel, S.S. Jick, Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin. Epidemiol. 9, 83–91 (2017)

    PubMed  PubMed Central  Google Scholar 

  62. M.J. Sikora, J.M. Rae, M.D. Johnson, Z. Desta, Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. HIV Med. 11(9), 603–607 (2010)

    CAS  PubMed  PubMed Central  Google Scholar 

  63. M. Chiba, L. Jin, W. Neway, J.P. Vacca, J.R. Tata, K. Chapman, J.H. Lin, P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra. Drug Metab. Dispos. 29(1), 1–3 (2001)

    CAS  PubMed  Google Scholar 

  64. D.S. Grosso, T.W. Boyden, R.W. Pamenter, D.G. Johnson, D.A. Stevens, J.N. Galgiani, Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. Antimicrob. Agents Chemother. 23(2), 207–212 (1983)

    CAS  PubMed  PubMed Central  Google Scholar 

  65. T.C. Fagan, D.G. Johnson, D.S. Grosso, Metronidazole-induced gynecomastia. JAMA 254(22), 3217 (1985)

    CAS  PubMed  Google Scholar 

  66. R. Dixit, S. Sharma, C.L. Nawal, Gynaecomastia during antituberculosis chemotherapy with isoniazid. J. Assoc. Physicians India 56, 390–391 (2008)

    PubMed  Google Scholar 

  67. N. Morrone, N. Morrone Jr, A.G. Braz, J.A. Maia, Gynecomastia: a rare adverse effect of isoniazid. J. Bras. Pneumol. 34(11), 978–981 (2008)

    PubMed  Google Scholar 

  68. L.A. Garcia Rodriguez, H. Jick, Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 308(6927), 503–506 (1994)

    CAS  PubMed  PubMed Central  Google Scholar 

  69. R.W. Spence, L.R. Celestin, Gynaecomastia associated with cimetidine. Gut 20(2), 154–157 (1979)

    CAS  PubMed  PubMed Central  Google Scholar 

  70. T. Poteat, A.L. Wirtz, A. Radix, A. Borquez, A. Silva-Santisteban, M.B. Deutsch, S.I. Khan, S. Winter, D. Operario, HIV risk and preventive interventions in transgender women sex workers. Lancet 385(9964), 274–286 (2015)

    PubMed  Google Scholar 

  71. S.D. Baral, T. Poteat, S. Stromdahl, A.L. Wirtz, T.E. Guadamuz, C. Beyrer, Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect. Dis. 13(3), 214–222 (2013)

    PubMed  Google Scholar 

  72. K.H. Mayer, B. Grinsztejn, W.M. El-Sadr, Transgender people and HIV prevention: what we know and what we need to know, a call to action. J. Acquir. Immune Defic. Syndr. 72(Suppl 3), S207–S209 (2016)

    PubMed  PubMed Central  Google Scholar 

  73. J.M. White Hughto, S.L. Reisner, J.E. Pachankis, Transgender stigma and health: a critical review of stigma determinants, mechanisms, and interventions. Soc. Sci. Med. 147, 222–231 (2015)

    PubMed  PubMed Central  Google Scholar 

  74. S.J. Hwahng, L. Nuttbrock, Sex workers, fem queens, and cross-dressers: differential marginalizations and HIV vulnerabilities among three ethnocultural male-to-female transgender communities in New York City. Sex. Res. Soc. Policy 4(4), 36–59 (2007)

    Google Scholar 

  75. S. Addis, M. Davies, G. Greene, S. Macbride-Stewart, M. Shepherd, The health, social care and housing needs of lesbian, gay, bisexual and transgender older people: a review of the literature. Health Soc. Care Commun. 17(6), 647–658 (2009)

    Google Scholar 

  76. J. Bradford, S.L. Reisner, J.A. Honnold, J. Xavier, Experiences of transgender-related discrimination and implications for health: results from the Virginia Transgender Health Initiative Study. Am. J. Public Health 103(10), 1820–1829 (2013)

    PubMed  PubMed Central  Google Scholar 

  77. J.B. Fletcher, K.A. Kisler, C.J. Reback, Housing status and HIV risk behaviors among transgender women in Los Angeles. Arch. Sex. Behav. 43(8), 1651–1661 (2014)

    PubMed  PubMed Central  Google Scholar 

  78. S.P. Kurtz, H.L. Surratt, M.C. Kiley, J.A. Inciardi, Barriers to health and social services for street-based sex workers. J. Health Care Poor Underserv. 16(2), 345–361 (2005)

    Google Scholar 

  79. K.L. Nadal, K.C. Davidoff, W. Fujii-Doe, Transgender women and the sex work industry: roots in systemic, institutional, and interpersonal discrimination. J. Trauma Dissociation 15(2), 169–183 (2014)

    PubMed  Google Scholar 

  80. J.D. Safer, E. Coleman, J. Feldman, R. Garofalo, W. Hembree, A. Radix, J. Sevelius, Barriers to healthcare for transgender individuals. Curr. Opin. Endocrinol. Diabetes Obes. 23(2), 168–171 (2016)

    PubMed  PubMed Central  Google Scholar 

  81. N.F. Sanchez, J.P. Sanchez, A. Danoff, Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. Am. J. Public Health 99(4), 713–719 (2009)

    PubMed  PubMed Central  Google Scholar 

  82. J.D. Safer, E.N. Pearce, A simple curriculum content change increased medical student comfort with transgender medicine. Endocr. Pract. 19(4), 633–637 (2013)

    PubMed  Google Scholar 

  83. D.D. Thomas, J.D. Safer, A simple intervention raised resident-physician willingness to assist transgender patients seeking hormone therapy. Endocr. Pract. 21(10), 1134–1142 (2015)

    PubMed  Google Scholar 

  84. A. Metastasio, A. Negri, G. Martinotti, O. Corazza, Transitioning bodies. The case of self-prescribing sexual hormones in gender affirmation in individuals attending psychiatric services. Brain Sci. 8(5), pii: E88 (2018)

    Google Scholar 

  85. C.J.M. de Blok, C.M. Wiepjes, N.M. Nota, K. van Engelen, M.A. Adank, K.M.A. Dreijerink, E. Barbe, I. Konings, M. den Heijer, Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 365, l1652 (2019)

    PubMed  PubMed Central  Google Scholar 

  86. Y. Kojima, N. Takahashi, N. Haga, M. Nomiya, T. Yanagida, K. Ishibashi, K. Aikawa, D.I. Lee, Urinary incontinence after robot-assisted radical prostatectomy: pathophysiology and intraoperative techniques to improve surgical outcome. Int. J. Urol. 20(11), 1052–1063 (2013)

    PubMed  Google Scholar 

Download references

Funding

This study was partially supported by the following external sources: X.C. is supported by National Institutes of Health (2R01CA151610) and Department of Defense (W81XWH-18-1-0067).

Author information

Authors and Affiliations

  1. Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Harsh Patel, Victor Arruarana, Lucille Yao, Xiaojiang Cui & Edward Ray

  2. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

    Harsh Patel & Edward Ray

Authors
  1. Harsh Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor Arruarana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lucille Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaojiang Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edward Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Ray.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with animals or human participants performed by any of the authors.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, H., Arruarana, V., Yao, L. et al. Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review. Endocrine 68, 6–15 (2020). https://doi.org/10.1007/s12020-020-02197-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-020-02197-5

Keywords

Search

Navigation